TOPIC
MECHANISM · DETAILS
FEATURES
CLUE
Androgen-dependent growth; age, Black men, family history, BRCA2, HOXB13, Lynch
Rare before 50; most common cancer in men, 2nd leading cancer death
Castrated men don't get it
Peripheral zone (posterior, palpable)
Usually asymptomatic; hard irregular nodule on DRE; urinary symptoms only when large; bone pain when metastatic
BPH is central (transition zone)
High-grade prostatic intraepithelial neoplasia (PIN)
Atypical cells within ducts, basal layer still present
Basal cells lost → invasion
Small crowded infiltrating glands with a single cell layer (no basal cells), prominent nucleoli; perineural invasion
AMACR ⁺; p63 and high-molecular-weight keratin ⁻ (no basal cells)
TMPRSS2-ERG fusion, PTEN loss
Grade by gland architecture, not nuclei; primary + secondary pattern (each 1–5)
Score 6–10, translated into Grade Groups 1–5
Higher score → worse prognosis
Serine protease that liquefies semen; prostate-specific, not cancer-specific
↑ in cancer, BPH, prostatitis, after ejaculation/instrumentation; ↓ free PSA fraction in cancer
Shared-decision screening 55–69 · monitors recurrence
Seminal vesicles, bladder base (obstruction), rectum (Denonvilliers fascia limits)
Obturator and iliac lymph nodes
Seminal vesicle invasion = worse stage
Through the valveless vertebral venous (Batson) plexus
Osteoblastic lesions in lumbar spine, pelvis; bone pain, ↑ ALP; risk of cord compression
Dense sclerotic lesions on X-ray
Radical prostatectomy or radiation; active surveillance for low grade
Prostatectomy risks: erectile dysfunction (cavernous nerves), incontinence
Low risk → watchful surveillance
GnRH agonist (leuprolide, continuous) → downregulation; antagonist (degarelix); AR blockers (flutamide, bicalutamide, enzalutamide); CYP17 inhibitor (abiraterone)
Hot flashes, ↓ libido, gynecomastia, osteoporosis, metabolic syndrome
Agonist "flare" in first weeks → add AR blocker
Castration-resistant disease
AR amplification/mutation, intratumoral androgen synthesis
Rising PSA despite castrate testosterone
Enzalutamide, abiraterone, docetaxel, PARP inhibitors (BRCA)